Celecoxib/amlodipine besylate: Additional Phase III data

Additional data from a double-blind, placebo-controlled, U.K. Phase III trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine

Read the full 241 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE